<DOC>
	<DOCNO>NCT00092534</DOCNO>
	<brief_summary>The primary purpose study determine Gardasil ( V501 ) investigational vaccine 4 component able prevent cervical cancer .</brief_summary>
	<brief_title>Cervical Intraepithelial Neoplasm ( CIN ) Women ( Gardasil ) ( V501-015 )</brief_title>
	<detailed_description>The original base study ( V501-015 ) ( NCT00092534 ) extend protocol V501-015-10 . Subjects placebo arm base study give 3 dos open-label GARDASIL™ ( V501 ) Extension ( EXT ) Day 1 , EXT Month 2 EXT Month 6 follow EXT Month 7 . Subjects receive 1 dose GARDASIL™ base study give 3 dos open-label GARDASIL™ ( V501 ) Extension ( EXT ) Day 1 , EXT Month 2 EXT Month 6 follow EXT Month 7 . Subjects receive 2 dos GARDASIL™ base study give 1 dose GARDASIL™ EXT Day 1 follow 15 day ( day vaccination plus 14 day ) . A second extension study , V501-015-20 , ass effectiveness , immunogenicity safety GARDASIL™ period 10-14 year follow completion base study ( V501-015 ) V501-015-10 extension . Subjects Denmark , Iceland , Norway Sweden participate base study eligible enroll . Effectiveness safety assess registry-based follow-up . Immunogenicity assess serological testing approximately Year 5 Year 10 V501-015-20 extension , respectively .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy woman intact uterus lifetime history 04 sexual partner For Extension Phase : Subject receive placebo incomplete vaccination series original study Prior Human Papilloma Virus ( HPV ) vaccination Prior abnormal Paps Prior history genital wart For Extension Phase : Prior complete HPV vaccination series Subject live country Gardasil approve within age range local labeling Gardasil</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>